Lexaria Bioscience Corp. filed a Form D with the Securities and Exchange Commission on 2026-09-21.
Lexaria Bioscience Corp. filed a Form D notice of an exempt securities offering with the SEC on September 21, 2026. Lexaria Bioscience Corp. trades on Nasdaq as LEXX; it was formerly Lexaria Corp. The filing reports $113K sold. Its industry group is Biotechnology. It names Christopher Bunka (Director), John Docherty (Executive Officer, Director), Richard Christopher (Executive Officer, Director) (SEC Form D, September 21, 2026).
In its own words: “Lexaria Bioscience Corp.'s DehydraTECH improves the way APIs enter the bloodstream by promoting more effective oral delivery.” (lexariabioscience.com, checked November 1, 2026)
Lexaria Bioscience Corp. raised on Sep 21. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Lexaria Bioscience Corp.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Lexaria Bioscience Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Lexaria Bioscience Corp.
Free to see. No signup.
More on the people and the money behind Lexaria Bioscience Corp., from the filings we hold.
H.C. WAINWRIGHT & CO. received sales compensation on this raise and on 28 other raises we hold, nearest in date first:
Biotechnology raises by companies based in the British Columbia, Canada, filed within 90 days of this one, largest first.
Get an email when Lexaria Bioscience Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Lexaria Bioscience Corp. raises, hires or launches. No email unless you switch it on.
Watch Lexaria Bioscience Corp. →Get the full cited report on Lexaria Bioscience Corp.
What the filing shows about Lexaria Bioscience Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexaria Bioscience Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Lexaria Bioscience Corp.'s address as 100 - 740 Mccurdy Road, Kelowna, A1 V1X 2P7.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Lexaria Bioscience Corp. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Lexaria Bioscience Corp. See pricing
Lexaria Bioscience Corp. is a registered filer with the SEC (CIK 1348362) and has filed since 2023-10-04. 7 filings are on record, the latest on 2026-09-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Lexaria Bioscience Corp.'s Form D of 2026-09-21 names Christopher Bunka, John Docherty, Richard Christopher and 5 more as its officers, directors or promoters.
Its new offerings report $18.15M sold across 7 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $113K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Lexaria Bioscience Corp.'s DehydraTECH improves the way APIs enter the bloodstream by promoting more effective oral delivery.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Christopher Bunka is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
John Docherty is named as Executive Officer and Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
Richard Christopher is named as Executive Officer and Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
Michael Shankman is named as Executive Officer on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
Nicholas Baxter is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
William McKechnie is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
Albert Reese is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
Bal Bhullar is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 21 September 2026, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2026-09-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Lexaria Bioscience Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexaria Bioscience Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexaria Bioscience Corp. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Lexaria Bioscience Corp.You get an alert in MentionFox the next time this company shows up.
If you're behind Lexaria Bioscience Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-27 (lexariabioscience.com).
Each opens in a new tab, filled in for Lexaria Bioscience Corp.. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-09-21 · Biotech raises, week of 2026-09-21
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/lexaria-bioscience-corp-form-d-000002